Hutchmed Shares Rise 5% After Positive Phase III Lung Cancer Trial Results

3-line summary

• Hutchmed shares rose 5% after the company reported positive results from a Phase III lung cancer clinical trial, according to an Investing.com report.

This summary is our own processing of the source article; see the source link below for full context.